Switching to Foundayo (Orforglipron) in 2026
Should you switch? 12-month decision math
Modeled at 220 lb starting weight, 12 months on each drug's self-pay-manufacturer channel. Your numbers will differ; use the full calculator to plug in your own.
| Currently on | Their monthly | Foundayo monthly | Monthly savings |
|---|---|---|---|
| Wegovy injection | $349 | $149 | $200 |
| Wegovy oral 25mg | $149 | $149 | $0 |
| Zepbound vials | $299 | $149 | $150 |
| Mounjaro (T2D) Mounjaro has no LillyDirect self-pay; $499/mo is typical branded telehealth | $499 | $149 | $350 |
Monthly savings is the headline number; $/lb tradeoff is the more accurate value comparison because it accounts for expected weight loss at trial efficacy levels. Foundayo's $66/lb at the lowest dose beats every other cash-pay path here except Zepbound starter vials. If you can stay at Foundayo's 0.8 mg dose, this is the cheapest serious GLP-1 path in 2026.
Switching from Wegovy injection to Foundayo
Save approximately $200/month at the lowest Foundayo dose. Trial efficacy is similar (14.9% Wegovy STEP-1 vs 14.7% Foundayo ATTAIN-1) so weight outcomes converge.
- You are paying NovoCare $349/month and the monthly cost is straining
- You prefer a daily oral pill over a weekly injection
- You tolerate Wegovy well at the lower doses and never needed to escalate to 2.4 mg
- You are NOT on Medicare yet (anti-kickback issue with the Foundayo Savings Card; the Medicare BALANCE Model only opens July 1, 2026)
Switching from Zepbound vials to Foundayo
Save approximately $150/month on monthly cost - but expected weight loss drops from 41.4 lb to 27 lb at 12 months. Cost-per-lb usually still favors Zepbound ($87/lb vs $66/lb).
- You cannot tolerate the GI side effects of Zepbound at any dose above 2.5 mg
- You strongly prefer an oral pill over a weekly injection
- Your goal weight loss is modest (less than 15% of body weight) so the trial-efficacy gap does not matter
- You are willing to accept slower progress in exchange for lower monthly out-of-pocket
- You have completed your weight-loss phase and want a cheaper maintenance medication
Switching from oral Wegovy 25mg to Foundayo
Same monthly cost ($149/mo at the starter tier). The decision is convenience-driven: Foundayo has NO fasting requirement; oral Wegovy 25mg requires an empty stomach and 30-minute wait. Trial efficacy is essentially tied (13.6% oral Wegovy OASIS-4 vs 14.7% Foundayo ATTAIN-1).
- You are struggling with the empty-stomach + 30-minute-wait routine for oral Wegovy
- Your morning schedule does not accommodate the fasting requirement
- You travel frequently and the fasting protocol is hard to maintain
- You have been on oral Wegovy for less than 8 weeks and have not yet escalated past 4 mg (switching gets easier the earlier in titration you are)
Switching from Mounjaro to Foundayo (non-diabetic patients only)
If you have type 2 diabetes, do NOT switch. Mounjaro is FDA-approved for T2D and your insurance is more likely to cover it. If you do NOT have diabetes and were using Mounjaro off-label for weight loss without insurance coverage, Foundayo at $149/month beats branded-telehealth Mounjaro at $499-$1,000+/month.
- If you have type 2 diabetes: stay on Mounjaro for the coverage advantage
- If you have no T2D: Zepbound LillyDirect vials at $299/month (same tirzepatide molecule as Mounjaro, FDA-approved for weight loss)
- If you have no T2D and want the cheapest possible cash-pay: Foundayo at $149/month
The prescriber switch protocol (what to expect at the visit)
- Stop your current GLP-1 on the last scheduled dose. No washout needed for GLP-1 to GLP-1 switching.
- Start Foundayo at 0.8 mg the next day. Most prescribers do not skip titration even for experienced GLP-1 patients because dose-response is molecule-specific.
- Titrate over 12-16 weeks. Standard schedule: 0.8 mg for 4 weeks → 2.5 mg for 4 weeks → 5.5 mg for 4 weeks → continue escalating to your prescriber-selected maintenance dose (9, 14.5, or 17.2 mg).
- Reorder via LillyDirect within the 45-day refill window to keep your dose-tier pricing. Outside the window, prices for the highest doses (14.5 mg and 17.2 mg) move from $299 to $349/month.
- Update your prescriber on tolerance every 4-6 weeks for the first 4 months. Foundayo GI side effects (nausea, constipation, diarrhea, fatigue) tend to be milder than tirzepatide or semaglutide at equivalent weight-loss levels, but individual response varies.
Three Foundayo payment paths to know before you switch
Use the Foundayo Savings Card. Lilly covers up to $100/mo of your insurer copay (annual cap $1,000, max 10 fills, expires 12/31/2026). If your old plan covered Wegovy or Zepbound, it very likely covers Foundayo too - new weight-loss GLP-1s typically land at the same formulary tier as existing ones.
The same Savings Card unlocks dose-tier self-pay through LillyDirect: $149 (0.8 mg) / $199 (2.5 mg) / $299 (5.5 mg and up). You just need commercial drug insurance, even if it excludes Foundayo.
Eligible Medicare Part D enrollees pay approximately $50/month under the CMS BALANCE demonstration. Confirm with your Part D plan administrator after July 1, 2026. Full Medicare path details.
Frequently asked questions
Is Foundayo cheaper than Wegovy?
Usually yes, at the lowest dose. Foundayo's LillyDirect self-pay starts at $149/month for the 0.8 mg dose, vs Wegovy NovoCare at $349/month for the injection ($349-$449 depending on dose). At equivalent commitment levels, Foundayo wins on monthly cost. At 12 months from 220 lb starting weight, expected loss is similar (~27 lb on Foundayo, 28 lb on Wegovy injection) because trial peak efficacy is close (14.7% Foundayo vs 14.9% Wegovy in their respective phase 3 trials). So cost-per-pound lost favors Foundayo when you stay at the low dose tier. The math reverses at Foundayo's $299/month higher-dose tier where Wegovy at $349 becomes competitive.
Is Foundayo cheaper than Zepbound?
On monthly cost: yes ($149-$299 vs Zepbound's $299-$449 via LillyDirect vials). On cost-per-pound-lost: usually no. Zepbound's phase 3 SURMOUNT-1 efficacy is 22.5% peak weight loss vs Foundayo's 14.7%. At 12 months, expected loss is 41.4 lb on Zepbound vs 27 lb on Foundayo from the same 220 lb starting weight. Even with the higher monthly cost, Zepbound's bigger weight delta usually wins on $/lb-lost. The exception: if you tolerate only the low dose of Foundayo ($149/mo) and would tolerate only the starter dose of Zepbound ($299/mo), Foundayo's lower monthly cost can win because Zepbound's higher tiers do not come into play.
Is Foundayo cheaper than oral Wegovy 25mg?
Tied at the lowest dose: both at $149/month. Foundayo's selling point is no fasting requirement (you can take it any time of day with food); oral Wegovy 25mg requires an empty stomach plus 30-minute wait. Trial efficacy is similar (14.7% Foundayo ATTAIN-1 vs 13.6% oral Wegovy OASIS-4). The convenience tradeoff usually pushes patients toward Foundayo at the same price point. Oral Wegovy may still be better for patients who already have a stable empty-stomach morning routine, who tolerate semaglutide well, or whose insurance has better oral-Wegovy coverage.
Should I switch from Mounjaro to Foundayo?
Probably not if you have type 2 diabetes. Mounjaro is FDA-approved for T2D so your insurance is more likely to cover it. Foundayo is FDA-approved for chronic weight management only - if you have diabetes, the T2D-indicated coverage path on Mounjaro is usually more valuable than the lower cash-pay price on Foundayo. If you do NOT have diabetes and were using Mounjaro off-label for weight loss without insurance coverage, then Foundayo at $149/month makes sense vs Mounjaro at $499-$1,000+/month branded telehealth. But for non-diabetic cash-pay patients, the cleaner choice is usually Zepbound via LillyDirect ($299/month starter vials, same tirzepatide molecule as Mounjaro, FDA-approved for weight loss) rather than Foundayo.
What does the prescriber switch protocol look like?
Standard practice: stop your current GLP-1 on your last scheduled dose, then start Foundayo at the 0.8 mg starter dose the next day. No washout period required for switching between GLP-1 receptor agonists. Most prescribers titrate Foundayo over 12-16 weeks regardless of whether you were on a higher dose of another GLP-1. Side effects during the switch are typically similar to or milder than initial GLP-1 introduction. Bring documentation of your current dose, tolerance history, and starting weight to the new prescriber consultation. Most prescribers will not skip Foundayo titration even for experienced GLP-1 patients because dose-response is drug-specific.
Will my weight come back during the switch?
Usually no, if the switch is done cleanly. Both drugs are GLP-1 receptor agonists; appetite suppression mechanism overlaps substantially. Patients sometimes report mild appetite return during the 1-2 week period when they are at the 0.8 mg starter dose of Foundayo (before reaching the 2.5 mg or higher dose where appetite suppression matches their old drug). Expect 2-5 lb of fluid weight fluctuation during this window; it is not true fat regain. If you stay adherent and complete the titration, weight loss typically resumes within 4-6 weeks.
What about side effects during the switch?
GLP-1 side effects (nausea, constipation, diarrhea, fatigue) often recur briefly during Foundayo titration even for experienced GLP-1 patients, because Foundayo is a different molecule (small-molecule non-peptide, not the peptide semaglutide or tirzepatide). The good news: trial data shows Foundayo GI side effects tend to be milder than semaglutide and tirzepatide at equivalent weight-loss levels. The bad news: you may have to repeat the slow-titration adjustment period you remember from when you first started a GLP-1.
Is there a "trial" or 30-day cancellation if I switch and Foundayo does not work?
No formal trial period from Eli Lilly. LillyDirect does not refund opened prescriptions. Practical workaround: order your first Foundayo fill at the 0.8 mg starter dose ($149) as a low-cost trial month. If you tolerate it, continue titration. If not, you have spent $149 and can switch back to your previous drug via a new prescription. Compared to $349-$449 for a starter month of Wegovy or Zepbound, Foundayo offers the cheapest "try it" entry into a new GLP-1.
Will my insurance cover Foundayo if it covered Wegovy or Zepbound?
Probably yes on most major commercial plans, but check first. Insurers tend to add new weight-loss GLP-1s to formulary at the same tier as existing weight-loss GLP-1s. Foundayo is FDA-approved for the same chronic-weight-management indication as Wegovy and Zepbound. Most plans will require a fresh prior authorization for the switch (BMI documentation, comorbidity ICD-10 code, prior weight-loss attempts). If your current Wegovy or Zepbound PA was approved, the Foundayo PA usually follows the same template. Allow 24-72 hours for commercial PA processing, 7-14 days for Medicare Advantage.
How do I switch to Foundayo if I am on Medicare?
Through the CMS BALANCE Model, which goes live July 1, 2026. Eligible Medicare Part D enrollees can pay approximately $50/month for Foundayo under BALANCE. The Wegovy Savings Card path does not work for Medicare patients (anti-kickback rules) but BALANCE is structurally different - it works through the Part D benefit itself. After July 1, contact your Part D plan administrator and ask whether they are a BALANCE participating plan and whether Foundayo is on formulary at the BALANCE tier. Until July 1, 2026, the only Medicare-eligible Foundayo path is LillyDirect cash self-pay ($149 lowest dose).
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.